Å. Kronblad

ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells

I. Hedenfalk, G. Landberg, S. Påhlman, 2005, Oncogene.

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

L. Rydén, N. Bengtsson, M. Stendahl, 2004, British Journal of Cancer.

Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.

G. Landberg, S. Påhlman, S. Beckman, 2003, Cancer research.

Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer.

G. Landberg, N. Nielsen, S. Emdin, 2003, In vivo.

Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.

K. Jirström, P. Bendahl, L. Rydén, 2005, Cancer research.

Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.

M. Ringnér, I. Hedenfalk, Srinivas Veerla, 2005 .

Hypoxia inducible factor‐1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response

K. Jirström, L. Rydén, B. Nordenskjöld, 2006, International journal of cancer.

CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance

R. Millikan, M. Duffy, L. Rydén, 2006, Clinical Cancer Research.